Atherosclerosis is a pathological condition of fat deposition in the arteries, which causes cardiovascular disorders. Management of
atherosclerosis remains a challenge and conventional drugs used for its management have several limitations. This study evaluated the protective effect of
tabersonine against
atherosclerosis and assessed its molecular mechanism of action.
METHODS: RESULTS: The
tabersonine-treatment groups had an improved
lipid profile and enhanced liver function, compared to the
ApoE treatment group.
Tabersonine treatment resulted in reduced levels of
nitric oxide,
cytokines, and oxidative stress, compared to the
ApoE group. The altered expression levels of
protein inhibitor activated STAT-3 (PIAS3), signal transducer and activator of transcription-3 (STAT-3), and nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor, alpha (IkBα) in
ApoE-deficient mice were ameliorated by
tabersonine treatment. Moreover, cAMP-response-element-binding (CREB) expression was elevated in aortic tissue of
tabersonine treatment groups, compared to the
ApoE group.
CONCLUSION: